1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. VBI VACCINES INC.

VBI Vaccines Inc.

XNAS: VBIVQ

Watchlist

Portfolio

Share


Insider Trading disclosures for VBI Vaccines Inc.

The latest disclosure was made by Steven Gillis in VBI Vaccines Inc. where a trade of 52,500 Option (Right to Buy Common Shares) done was reported to US exchanges on July 27, 2023.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Steven Gillis Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jul 2023 52,500 52,500 - - Option (Right to Buy Common Shares)
Vaughn B. Himes Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jul 2023 35,000 35,000 - - Option (Right to Buy Common Shares)
Avi Mazaltov Head Global MFG&GM-SciVac Ltd. Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jul 2023 52,500 52,500 - - Option (Right to Buy Common Shares)
Jeffrey R. Baxter Director, CEO, President Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jul 2023 70,000 70,000 - - Option (Right to Buy Common Shares)
David E. Anderson Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jul 2023 52,500 52,500 - - Option (Right to Buy Common Shares)
Michel De Wilde Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jul 2023 35,000 35,000 - - Option (Right to Buy Common Shares)
Nell Beattie Director, CFO, Head of Corp. Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jul 2023 52,500 52,500 - - Option (Right to Buy Common Shares)
Francisco Diaz-Mitoma Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jul 2023 52,500 52,500 - - Option (Right to Buy Common Shares)
Joanne Cordeiro Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jul 2023 35,000 35,000 - - Option (Right to Buy Common Shares)
Damian Braga Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jul 2023 35,000 35,000 - - Option (Right to Buy Common Shares)
John Robert Dillman Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jul 2023 52,500 52,500 - - Option (Right to Buy Common Shares)
Steven Gillis Director Purchase of securities on an exchange or from another person at price $ 1.65 per share. 10 Jul 2023 609,090 1,043,292 (0%) 0% 1.7 1,004,999 Common Shares, no par value per share
Steven Gillis Director Purchase of securities on an exchange or from another person at price $ 0.00 per share. 10 Jul 2023 609,090 609,090 - - Warrant (right to buy)
Vaughn B. Himes Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Apr 2023 8,000 8,000 - - Option (Right to Buy Common Shares)
Steven Gillis Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 Jan 2023 75,000 75,000 - - Option (Right to Buy Common Shares)
Avi Mazaltov Head Global MFG&GM-SciVac Ltd. Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 Jan 2023 75,000 75,000 - - Option (Right to Buy Common Shares)
Jeffrey R. Baxter Director, CEO, President Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 Jan 2023 100,000 100,000 - - Option (Right to Buy Common Shares)
David E. Anderson Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 Jan 2023 75,000 75,000 - - Option (Right to Buy Common Shares)
Michel De Wilde Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 Jan 2023 50,000 50,000 - - Option (Right to Buy Common Shares)
Nell Beattie Chief Business Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 Jan 2023 75,000 75,000 - - Option (Right to Buy Common Shares)
Francisco Diaz-Mitoma Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 Jan 2023 75,000 75,000 - - Option (Right to Buy Common Shares)
Christopher McNulty Director, CFO and Head of BD Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 Jan 2023 75,000 75,000 - - Option (Right to Buy Common Shares)
Joanne Cordeiro Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 Jan 2023 50,000 50,000 - - Option (Right to Buy Common Shares)
Damian Braga Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 Jan 2023 50,000 50,000 - - Option (Right to Buy Common Shares)
John Robert Dillman Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 Jan 2023 75,000 75,000 - - Option (Right to Buy Common Shares)
John Robert Dillman Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 07 Jul 2022 100,000 100,000 - - Option (Right to Buy Common Shares)
Steven Gillis Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2022 100,000 100,000 - - Option (Right to Buy Common Shares)
Avi Mazaltov Head Global MFG&GM-SciVac Ltd. Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2022 400,000 400,000 - - Option (Right to Buy Common Shares)
Linda C. Bain Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2022 75,000 75,000 - - Option (Right to Buy Common Shares)
Jeffrey R. Baxter Director, CEO, President Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2022 800,000 800,000 - - Option (Right to Buy Common Shares)
David E. Anderson Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2022 400,000 400,000 - - Option (Right to Buy Common Shares)
Michel De Wilde Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2022 75,000 75,000 - - Option (Right to Buy Common Shares)
Nell Beattie Chief Business Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2022 400,000 400,000 - - Option (Right to Buy Common Shares)
Francisco Diaz-Mitoma Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2022 400,000 400,000 - - Option (Right to Buy Common Shares)
Christopher McNulty Director, CFO and Head of BD Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2022 400,000 400,000 - - Option (Right to Buy Common Shares)
Joanne Cordeiro Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2022 75,000 75,000 - - Option (Right to Buy Common Shares)
Damian Braga Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2022 75,000 75,000 - - Option (Right to Buy Common Shares)
Nell Beattie Chief Business Officer Purchase of securities on an exchange or from another person at price $ 2.45 per share. 03 Dec 2021 8,200 68,200 (0%) 0% 2.4 20,083 Common Shares, no par value per share
Linda C. Bain Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jul 2021 250,000 250,000 - - Option (Right to Buy Common Shares)
Steven Gillis Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2021 100,000 100,000 - - Option (Right to Buy Common Shares)
Avi Mazaltov Head Global MFG&GM-SciVac Ltd. Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2021 500,000 500,000 - - Option (Right to Buy Common Shares)
Jeffrey R. Baxter Director, CEO, President Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2021 1,000,000 1,000,000 - - Option (Right to Buy Common Shares)
David E. Anderson Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2021 500,000 500,000 - - Option (Right to Buy Common Shares)
Michel De Wilde Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2021 75,000 75,000 - - Option (Right to Buy Common Shares)
Nell Beattie Chief Business Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2021 500,000 500,000 - - Option (Right to Buy Common Shares)
Francisco Diaz-Mitoma Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2021 500,000 500,000 - - Option (Right to Buy Common Shares)
Christopher McNulty Director, CFO and Head of BD Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2021 500,000 500,000 - - Option (Right to Buy Common Shares)
Joanne Cordeiro Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2021 75,000 75,000 - - Option (Right to Buy Common Shares)
Damian Braga Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2021 75,000 75,000 - - Option (Right to Buy Common Shares)
Avi Mazaltov Head Global MFG&GM-SciVac Ltd. Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jul 2020 167,150 167,150 - - Option (Right to Buy Common Shares)
Jeffrey R. Baxter Director, CEO, President Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jul 2020 425,200 425,200 - - Option (Right to Buy Common Shares)
David E. Anderson Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jul 2020 170,100 170,100 - - Option (Right to Buy Common Shares)
Nell Beattie Chief Business Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jul 2020 170,100 170,100 - - Option (Right to Buy Common Shares)
Francisco Diaz-Mitoma Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jul 2020 167,150 167,150 - - Option (Right to Buy Common Shares)
Christopher McNulty Director, CFO and Head of BD Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jul 2020 170,100 170,100 - - Option (Right to Buy Common Shares)
Damian Braga None Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 Mar 2020 250,000 250,000 - - Option (Right to Buy Common Shares)
Steven Gillis None Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 Jan 2020 350,000 350,000 - - Option (Right to Buy Common Shares)
Avi Mazaltov Head Global MFG&GM-SciVac Ltd. Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 Jan 2020 50,000 50,000 - - Restricted Stock Units
Jeffrey R. Baxter Director, CEO, President Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 Jan 2020 500,000 500,000 - - Option (Right to Buy Common Shares)
David E. Anderson Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 Jan 2020 350,000 350,000 - - Option (Right to Buy Common Shares)
Michel De Wilde None Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 Jan 2020 250,000 250,000 - - Option (Right to Buy Common Shares)
Nell Beattie Chief Business Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 Jan 2020 350,000 350,000 - - Option (Right to Buy Common Shares)
Francisco Diaz-Mitoma Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 Jan 2020 350,000 350,000 - - Option (Right to Buy Common Shares)
Christopher McNulty Director, CFO and Head of BD Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 Jan 2020 350,000 350,000 - - Option (Right to Buy Common Shares)
Joanne Cordeiro None Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 Jan 2020 250,000 250,000 - - Option (Right to Buy Common Shares)
Nell Beattie Chief Business Officer Purchase of securities on an exchange or from another person at price $ 0.48 per share. 01 Oct 2019 10,000 60,000 (0%) 0% 0.5 4,822 Common Shares, no par value per share
Christopher McNulty Director, CFO and Head of BD Purchase of securities on an exchange or from another person at price $ 0.47 per share. 01 Oct 2019 12,000 37,000 (0%) 0% 0.5 5,676 Common Shares, no par value per share
Jeffrey R. Baxter Director, CEO, President Purchase of securities on an exchange or from another person at price $ 0.50 per share. 30 Sep 2019 150,000 608,255 (0%) 0% 0.5 75,450 Common Shares, no par value per share
Francisco Diaz-Mitoma Chief Medical Officer Purchase of securities on an exchange or from another person at price $ 0.50 per share. 30 Sep 2019 14,500 14,500 (0%) 0% 0.5 7,250 Common Shares, no par value per share
Francisco Diaz-Mitoma Chief Medical Officer Purchase of securities on an exchange or from another person at price $ 0.50 per share. 30 Sep 2019 40,000 117,500 (0%) 0% 0.5 20,000 Common Shares, no par value per share
Francisco Diaz-Mitoma Chief Medical Officer Purchase of securities on an exchange or from another person at price $ 0.78 per share. 20 Jun 2019 10,000 27,500 (0%) 0% 0.8 7,800 Common Shares, no par value per share
Francisco Diaz-Mitoma Chief Medical Officer Purchase of securities on an exchange or from another person at price $ 0.89 per share. 20 Jun 2019 42,000 69,500 (0%) 0% 0.9 37,380 Common Shares, no par value per share
Jeffrey R. Baxter Director, CEO, President Purchase of securities on an exchange or from another person at price $ 0.73 per share. 19 Jun 2019 144,000 458,255 (0%) 0% 0.7 105,336 Common Shares, no par value per share
Nell Beattie Chief Business Officer Purchase of securities on an exchange or from another person at price $ 0.74 per share. 19 Jun 2019 8,000 50,000 (0%) 0% 0.7 5,886 Common Shares, no par value per share
Steven Gillis None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2019 18,750 84,416 (0%) 0% - Common Shares, no par value per share
Steven Gillis None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2019 18,750 0 - - Restricted Stock Units (RSUs)
Jeffrey R. Baxter Director, CEO, President Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2019 31,250 0 - - Restricted Stock Units (RSUs)
Jeffrey R. Baxter Director, CEO, President Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2019 31,250 314,255 (0%) 0% - Common Shares, no par value per share
David E. Anderson Chief Scientific Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2019 21,875 148,209 (0%) 0% - Common Shares, no par value per share
David E. Anderson Chief Scientific Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2019 21,875 0 - - Restricted Stock Units (RSUs)
Michel De Wilde None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2019 12,500 50,000 (0%) 0% - Common Shares, no par value per share
Michel De Wilde None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2019 12,500 0 - - Restricted Stock Units (RSUs)
Nell Beattie Chief Business Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2019 6,250 42,000 (0%) 0% - Common Shares, no par value per share
Nell Beattie Chief Business Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2019 6,250 0 - - Restricted Stock Units (RSUs)
Joanne Cordeiro None Grant, award, or other acquisition of securities at price $ 0.00 per share. 18 Apr 2019 200,000 200,000 - - Option (Right to Buy Common Shares)
Steven Gillis None Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2019 300,000 300,000 - - Option (Right to Buy Common Shares)
Avi Mazaltov Head Global MFG&GM-SciVac Ltd. Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2019 90,000 196,000 (0%) 0% 0 Common Share
Tomer Kariv None Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2019 200,000 200,000 - - Option (Right to Buy Common Shares)
Jeffrey R. Baxter Director, CEO, President Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2019 450,000 450,000 - - Option (Right to Buy Common Shares)
Jeffrey R. Baxter Director, CEO, President Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2019 50,000 283,005 (0%) 0% 0 Common Shares, no par value per share
David E. Anderson Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2019 25,000 126,334 (0%) 0% 0 Common Shares, no par value per share
David E. Anderson Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2019 300,000 300,000 - - Option (Right to Buy Common Shares)
Michel De Wilde None Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2019 200,000 200,000 - - Option (Right to Buy Common Shares)
Scott Requadt None Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2019 200,000 200,000 - - Option (Right to Buy Common Shares)
Nell Beattie Chief Business Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2019 300,000 300,000 - - Option (Right to Buy Common Shares)
Nell Beattie Chief Business Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2019 15,000 35,750 (0%) 0% 0 Common Shares, no par value per share
Francisco Diaz-Mitoma Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2019 300,000 300,000 - - Option (Right to Buy Common Shares)
Christopher McNulty CFO and Head of BD Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2019 300,000 300,000 - - Option (Right to Buy Common Shares)
Christopher McNulty CFO and Head of BD Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2019 25,000 25,000 (0%) 0% 0 Common Shares, no par value per share
Tomer Kariv None Purchase of securities on an exchange or from another person at price $ 1.40 per share. 17 Dec 2018 612,997 1,744,969 (2%) 0% 1.4 858,196 Common Stock
Tomer Kariv None Purchase of securities on an exchange or from another person at price $ 1.40 per share. 17 Dec 2018 298,431 849,520 (1%) 0% 1.4 417,803 Common Stock
Tomer Kariv None Purchase of securities on an exchange or from another person at price $ 1.40 per share. 17 Dec 2018 331,429 943,451 (1%) 0% 1.4 464,001 Common Stock
Tomer Kariv None Purchase of securities on an exchange or from another person at price $ 1.40 per share. 17 Dec 2018 185,714 185,714 (0%) 0% 1.4 260,000 Common Stock
Christopher McNulty CFO and Head of BD Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Sep 2018 250,000 250,000 - - Option (Right to Buy Common Shares)
Jeffrey R. Baxter Director, CEO, President Purchase of securities on an exchange or from another person at price $ 1.93 per share. 06 Aug 2018 8,100 233,005 (0%) 0% 1.9 15,607 Common Shares, no par value per share
Jeffrey R. Baxter Director, CEO, President Purchase of securities on an exchange or from another person at price $ 2.01 per share. 03 Aug 2018 13,500 224,905 (0%) 0% 2.0 27,111 Common Shares, no par value per share
Nell Beattie Chief Business Officer Purchase of securities on an exchange or from another person at price $ 2.01 per share. 03 Aug 2018 2,000 20,750 (0%) 0% 2.0 4,011 Common Shares, no par value per share
Francisco Diaz-Mitoma Chief Medical Officer Purchase of securities on an exchange or from another person at price $ 2.20 per share. 02 Aug 2018 3,000 11,500 (0%) 0% 2.2 6,600 Common Shares, no par value per share
Francisco Diaz-Mitoma Chief Medical Officer Purchase of securities on an exchange or from another person at price $ 2.10 per share. 02 Aug 2018 6,000 17,500 (0%) 0% 2.1 12,600 Common Shares, no par value per share
Jeffrey R. Baxter Director, CEO, President Purchase of securities on an exchange or from another person at price $ 2.28 per share. 31 Jul 2018 16,800 211,405 (0%) 0% 2.3 38,237 Common Shares, no par value per share
Steven Gillis None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2018 18,750 65,666 (0%) 0% 0 Common Shares, no par value per share
Steven Gillis None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2018 18,750 18,750 - - Restricted Stock Units (RSUs)
Adam E. Logal None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2018 12,500 12,500 - - Restricted Stock Units (RSUs)
Adam E. Logal None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2018 12,500 37,500 (0%) 0% 0 Common Shares, no par value per share
Steven D. Rubin None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2018 18,750 18,750 - - Restricted Stock Units (RSUs)
Steven D. Rubin None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2018 18,750 56,250 (0%) 0% 0 Common Shares, no par value per share
Jeffrey R. Baxter Director, CEO, President Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2018 31,250 31,250 - - Restricted Stock Units (RSUs)
Jeffrey R. Baxter Director, CEO, President Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2018 31,250 194,605 (0%) 0% 0 Common Shares, no par value per share
David E. Anderson Chief Scientific Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.76 per share. 14 Jun 2018 9,281 101,334 (0%) 0% 3.8 34,897 Common Shares, no par value per share
Michel De Wilde None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2018 12,500 12,500 - - Restricted Stock Units (RSUs)
Michel De Wilde None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2018 12,500 37,500 (0%) 0% 0 Common Shares, no par value per share
Scott Requadt None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2018 12,500 37,500 (0%) 0% 0 Common Shares, no par value per share
Scott Requadt None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2018 12,500 12,500 - - Restricted Stock Units (RSUs)
Nell Beattie Chief Business Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2018 6,250 18,750 (0%) 0% 0 Common Shares, no par value per share
Nell Beattie Chief Business Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2018 6,250 6,250 - - Restricted Stock Units (RSUs)
Jeffrey R. Baxter Director, CEO, President Purchase of securities on an exchange or from another person at price $ 2.99 per share. 24 May 2018 11,000 163,355 (0%) 0% 3.0 32,890 Common Shares, no par value per share
Jeffrey R. Baxter Director, CEO, President Purchase of securities on an exchange or from another person at price $ 2.91 per share. 11 May 2018 7,100 152,355 (0%) 0% 2.9 20,661 Common Shares, no par value per share
Francisco Diaz-Mitoma Chief Medical Officer Purchase of securities on an exchange or from another person at price $ 3.13 per share. 11 May 2018 4,500 268,839 (0%) 0% 3.1 14,085 Common Shares, no par value
Francisco Diaz-Mitoma Chief Medical Officer Purchase of securities on an exchange or from another person at price $ 2.98 per share. 11 May 2018 5,500 8,500 (0%) 0% 3.0 16,390 Common Shares, no par value
Steven Gillis None Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Jan 2018 100,000 100,000 - - Option (Right to Buy Common Shares)
Adam E. Logal None Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Jan 2018 75,000 75,000 - - Option (Right to Buy Common Shares)
Steven D. Rubin None Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Jan 2018 75,000 75,000 - - Option (Right to Buy Common Shares)
Avi Mazaltov Head Global MFG&GM-SciVac Ltd. Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Jan 2018 100,000 106,000 (0%) 0% 0 Common Share
Tomer Kariv None Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Jan 2018 75,000 75,000 - - Option (Right to Buy Common Shares)
Jeffrey R. Baxter Director, CEO, President Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Jan 2018 150,000 150,000 - - Option (Right to Buy Common Shares)
David E. Anderson Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Jan 2018 100,000 100,000 - - Option (Right to Buy Common Shares)
T. Adam Buckley VP, Business Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Jan 2018 75,000 75,000 - - Option (Right to Buy Common Shares)
Michel De Wilde None Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Jan 2018 75,000 75,000 - - Option (Right to Buy Common Shares)
Scott Requadt None Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Jan 2018 75,000 75,000 - - Option (Right to Buy Common Shares)
Nell Beattie Chief Business Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Jan 2018 100,000 100,000 - - Option (Right to Buy Common Shares)
Francisco Diaz-Mitoma Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Jan 2018 100,000 100,000 - - Option (Right to Buy Common Shares)
Athena Kartsaklis SVP Finance, CCO Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Jan 2018 75,000 75,000 - - Option (Right to Buy Common Shares)
Jeffrey R. Baxter Director, CEO, President Purchase of securities on an exchange or from another person at price $ 3.88 per share. 12 Dec 2017 4,609 145,255 (0%) 0% 3.9 17,883 Common Shares, no par value per share
Jeffrey R. Baxter Director, CEO, President Purchase of securities on an exchange or from another person at price $ 3.89 per share. 12 Dec 2017 5,391 140,646 (0%) 0% 3.9 20,971 Common Shares, no par value per share
Jeffrey R. Baxter Director, CEO, President Purchase of securities on an exchange or from another person at price $ 4.75 per share. 28 Nov 2017 15,000 135,255 (0%) 0% 4.8 71,250 Common Shares, no par value per share
Steven Gillis None Purchase of securities on an exchange or from another person at price $ 3.05 per share. 30 Oct 2017 300,000 3,026,057 (7%) 0% 3.1 915,000 Common Shares, no par value per share
Sam Chawla None Purchase of securities on an exchange or from another person at price $ 3.05 per share. 30 Oct 2017 3,100,000 9,345,725 (23%) 7% 3.1 9,455,000 Common Shares, no par value per share
Jeffrey R. Baxter Director, CEO, President Purchase of securities on an exchange or from another person at price $ 3.22 per share. 21 Aug 2017 10,000 120,255 (0%) 0% 3.2 32,200 Common Shares, no par value per share
Francisco Diaz-Mitoma Chief Medical Officer Purchase of securities on an exchange or from another person at price $ 3.17 per share. 21 Aug 2017 3,000 3,000 (0%) 0% 3.2 9,510 Common Shares, no par value per share
Jeffrey R. Baxter Director, CEO, President Purchase of securities on an exchange or from another person at price $ 3.28 per share. 10 Aug 2017 10,000 110,255 (0%) 0% 3.3 32,800 Common Shares, no par value per share
Francisco Diaz-Mitoma Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 Jun 2017 12,500 264,339 (0%) 0% 0 Common Shares, no par value per share
Steven Gillis None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2017 18,750 46,916 (0%) 0% 0 Common Shares, no par value per share
Steven Gillis None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2017 18,750 37,500 - - Restricted Stock Units (RSUs)
Adam E. Logal None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2017 12,500 25,000 - - Restricted Stock Units (RSUs)
Adam E. Logal None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2017 12,500 25,000 (0%) 0% 0 Common Shares, no par value per share
Steven D. Rubin None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2017 18,750 37,500 (0%) 0% 0 Common Shares, no par value per share
Steven D. Rubin None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2017 18,750 37,500 - - Restricted Stock Units (RSUs)
Sam Chawla None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2017 12,500 25,000 (0%) 0% 0 Common Shares, no par value per share
Sam Chawla None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2017 12,500 25,000 - - Restricted Stock Units (RSUs)
Jeffrey R. Baxter Director, CEO, President Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2017 31,250 62,500 - - Restricted Stock Units (RSUs)
Jeffrey R. Baxter Director, CEO, President Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2017 31,250 100,255 (0%) 0% 0 Common Shares, no par value per share
David E. Anderson Chief Scientific Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2017 21,875 43,750 - - Restricted Stock Units (RSUs)
David E. Anderson Chief Scientific Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2017 21,875 88,740 (0%) 0% 0 Common Shares, no par value per share
T. Adam Buckley VP, Business Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2017 4,687 9,374 - - Restricted Stock Units (RSUs)
T. Adam Buckley VP, Business Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2017 4,687 44,063 (0%) 0% 0 Common Shares, no par value per share
Michel De Wilde None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2017 12,500 25,000 - - Restricted Stock Units (RSUs)
Michel De Wilde None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2017 12,500 25,000 (0%) 0% 0 Common Shares, no par value per share
Scott Requadt None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2017 12,500 25,000 (0%) 0% 0 Common Shares, no par value per share
Scott Requadt None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2017 12,500 25,000 - - Restricted Stock Units (RSUs)
Nell Beattie DCD Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2017 6,250 12,500 - - Restricted Stock Units (RSUs)
Nell Beattie DCD Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Jun 2017 6,250 12,500 (0%) 0% 0 Common Shares, no par value per share
Jeffrey R. Baxter Director, CEO, President Grant, award, or other acquisition of securities at price $ 0.00 per share. 18 Apr 2017 20,000 20,000 - - Option (Right to Buy Common Shares)
Michel De Wilde None Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Apr 2017 12,500 12,500 - - Option (Right to Buy Common Shares)
Nell Beattie Director, Corp Development/IR Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Apr 2017 20,000 20,000 - - Option (Right to Buy Common Shares)
David E. Anderson Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Mar 2017 20,000 20,000 - - Option (Right to Buy Common Shares)
Scott Requadt None Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Mar 2017 12,500 12,500 - - Option (Right to Buy Common Shares)
Catherine Eckenswiller Contracts and IP Counsel Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Mar 2017 3,000 3,000 - - Option (Right to Buy Common Shares)
Adam E. Logal None Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Mar 2017 12,500 12,500 - - Option (Right to Buy Common Shares)
Steven D. Rubin None Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Mar 2017 12,500 12,500 - - Option (Right to Buy Common Shares)
Sam Chawla None Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Mar 2017 12,500 12,500 - - Option (Right to Buy Common Shares)
Egidio Nascimento Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Mar 2017 20,000 20,000 - - Option (Right to Buy Common Shares)
T. Adam Buckley VP, Business Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Mar 2017 20,000 20,000 - - Option (Right to Buy Common Shares)
Francisco Diaz-Mitoma Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 29 Mar 2017 12,500 251,839 (0%) 0% 0 Common Shares, no par value per share
Francisco Diaz-Mitoma Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 29 Mar 2017 20,000 20,000 - - Option (Right to Buy Common Shares)
Steven Gillis None Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.50 per share. 17 Jan 2017 6,377 28,166 (0%) 0% 2.5 15,943 Common Shares, no par value per share
Steven Gillis None Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Jan 2017 15,000 15,000 - - Option (Right to Buy Common Shares)
Steven Gillis None Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 17 Jan 2017 6,377 0 - - Option (Right to Buy Common Shares)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures
Screeners based on Insider Trading and SAST parameters